Tag: signals

TALLINN, Estonia, June 29, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris (BTC-S), the next-generation blockchain platform focused on scalability and real-world utility, has crossed a major milestone in its ongoing presale—raising over $5 million as it enters Phase 9. With the token price now at $9 and a public launch target of $20, early investors are eyeing a potential 150% gain before the scheduled launch in just under six weeks. Amidst ongoing crypto market volatility, Bitcoin Solaris is emerging as a rare opportunity grounded in technical innovation, sustainability, and long-term value creation.

TALLINN, Estonia, June 27, 2025 (GLOBE NEWSWIRE) -- In a market dominated by noise and recycled narratives, something unexpected has caught the attention of serious crypto watchers. According to fresh data trends and early portfolio analytics on Live Coin Watch, Bitcoin Solaris is now being flagged as the most undervalued presale opportunity in the current cycle. And for once, the data matches the hype.

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

American Century's chief investment officers' insights on patience amid off-the-charts uncertainty KANSAS CITY, Mo., June 26, 2025 /PRNewswire/ -- Amid a year marked by economic...

XI'AN, China , June 26, 2025 /PRNewswire/ -- Smartee Denti-Technology recently hosted international orthodontic experts and partners at a global symposium in Xi'an, China. Twenty-four Clinicians...

Following a 198% sales surge in Q4, Hapbee added 191% revenue growth in Q1 2025 while reducing operating expenses by 62%

Following a 198% sales surge in Q4, Hapbee added 191% revenue growth in Q1 2025 while reducing operating expenses by 62%

DAYTON, Ohio and CINCINNATI, June 25, 2025 /PRNewswire/ -- Independent creative strategy, branding, and experience design agency Hyperquake today announced its role in developing...

ENGLEWOOD, Colo., June 25, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices...

Hole MD-047 intercepted visible copper and molybdenum mineralization from surface to the end of the hole (EOH). First 489m assayed 0.45% CuEq* (0.35% Cu...

Innovative needle-free technology empowers users to monitor glucose signals, oxygen saturation, and heart rate from home—without the discomfort or complexity of traditional tools.

Innovative needle-free technology empowers users to monitor glucose signals, oxygen saturation, and heart rate from home—without the discomfort or complexity of traditional tools.

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...